Paraza Pharma, a Canada-based, fully integrated drug discovery organisation, announced on Monday that it has named Dr Chudi Ndubaku as its new chief scientific officer.
In the new role, Dr Ndubaku is to head and drive the strategic growth of the company's R&D division, with unitary focus to further improve the scientific impact of Paraza research on client-partners' programs.
Dr Ndubaku has held various senior scientific leadership positions at Genentech, Aduro Biotech and ORIC Pharmaceuticals.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer